Teams up with leading dermatologist

Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.

The agreement concerns the wound healing treatment Chronseal, a product jointly owned by Tripep and their japanese partner company Kringle Pharma. The letter of intent is signed with the japanese specialty pharma company Maruho, the largest dermatology company of Japan, granting them the rights to, as first company, evaluate the results from an on-going phase I/II study of Chronseal. The agreement also grants Maruho the rights to negotiate the sales rights for Chronseal on the Japanese market.

Two clinical pilot studies on Chronseal have been successfully conducted on a total of 24 patients with chronic leg ulcers. Tripep has recently started a multicenter phase I//II study.